Study of NTBC for Tyrosinemia I

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2000 by FDA Office of Orphan Products Development.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
University of Washington
Information provided by:
FDA Office of Orphan Products Development
ClinicalTrials.gov Identifier:
NCT00004443
First received: October 18, 1999
Last updated: June 23, 2005
Last verified: April 2000

October 18, 1999
June 23, 2005
October 1998
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00004443 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of NTBC for Tyrosinemia I
Not Provided

OBJECTIVES: I. Assess the safety and efficacy of NTBC in children with tyrosinemia I.

II. Evaluate the effects of NTBC on survival, rate of neurologic crises, improvement in renal tubular damage, reduction in the need for liver transplantation, and reduction in the development of hepatocarcinoma in these patients.

PROTOCOL OUTLINE: Patients are stratified according to age at onset of symptoms (0-2 months vs 2-6 months vs greater than 6 months).

Patients receive oral NTBC twice a day. Treatment continues in the absence of unacceptable toxicity.

Patients are followed once a month for 6 months, then every 3 months thereafter.

Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
Tyrosinemia I
Drug: NTBC
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
Not Provided
Not Provided
  • Confirmed diagnosis of tyrosinemia Detected through newborn screening before the onset of symptoms OR Diagnosed on the basis of symptoms (liver disease, neurological crises, growth failure) and succinylacetone in urine or blood and/or fumarylacetoacetate dehydratase deficiency in cultured fibroblasts or liver biopsy
Both
up to 17 Years
No
United States,   Canada
 
NCT00004443
199/13443, UWASH-FDR001445
Not Provided
Not Provided
FDA Office of Orphan Products Development
University of Washington
Study Chair: C. Ronald Scott University of Washington
FDA Office of Orphan Products Development
April 2000

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP